| Study |
Reference |
|
Al Khalaf - Methyldopa (Controls unexposed, disease free), 2022
|
Al Khalaf Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: a Population-Based Study of Linked Electronic Health Records. Hypertension 2022; 79:1548-1558
|
|
Al Khalaf - Methyldopa (Controls unexposed, sick), 2022
|
Al Khalaf Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: a Population-Based Study of Linked Electronic Health Records. Hypertension 2022; 79:1548-1558
|
|
Chan - Methyldopa, 2010
|
Chan WS Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy 2010;29:271-83
|
|
De Jonge - Methyldopa, 2013
|
de Jonge Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection. Drug Saf 2013; 36:1069-78
|
|
Fidler - Methyldopa, 1983
|
Fidler Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br Med J (Clin Res Ed) 1983; 286:1927-30
|
|
Fisher - Centrally acting antiadrenergics (Controls unexposed, disease free), 2017
|
Fisher Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension 2017; 69:798-805
|
|
Fisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017
|
Fisher Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension 2017; 69:798-805
|
|
Fisher a - Centrally acting, 2018
|
Fisher Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res 2018; 110:1433-1442
|
|
Fisher b - Centrally acting (Controls unexposed, disease free), 2018
|
Fisher Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997-2011. Matern Child Health J 2018; 22:237-246
|
|
Fisher b - Centrally acting (Controls unexposed, sick), 2018
|
Fisher Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997-2011. Matern Child Health J 2018; 22:237-246
|
|
Fitton - Centrally acting, 2021
|
Fitton Congenital defects and early childhood outcomes following in-utero exposure to antihypertensive medication. J Hypertens 2021; 39:581-588
|
|
Fitton - Centrally acting (Controls unexposed, disease free), 2020
|
Fitton In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study. Hypertension 2020; 75:628-633
|
|
Fitton - Centrally acting (Controls unexposed, sick), 2020
|
Fitton In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study. Hypertension 2020; 75:628-633
|
|
Hoeltzenbein - Methyldopa (Controls unexposed, disease free), 2017
|
Hoeltzenbein M Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension 2017;70:201-208
|
|
Huisjes - Clonidine, 1986
|
Huisjes Is clonidine a behavioural teratogen in the human? Early Hum Dev 1986; 14:43-8
|
|
Ishikawa - Methyldopa (Controls unexposed, disease free), 2023
|
Ishikawa Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019. Pregnancy Hypertens 2023; 31:73-83
|
|
Ishikawa - Methyldopa (Controls unexposed, sick), 2023
|
Ishikawa Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019. Pregnancy Hypertens 2023; 31:73-83
|
|
Kayser - Methyldopa, 2020
|
Kayser Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. J Hypertens 2020; 38:354-361
|
|
Leather - Methyldopa, 1968
|
Leather A controlled trial of hypotensive agents in hypertension in pregnancy. Lancet 1968; 2:488-90
|
|
Mabie - Methyldopa, 1986
|
Mabie Chronic hypertension in pregnancy. Obstet Gynecol 1986; 67:197-205
|
|
Medveczky - Methyldopa, 2004
|
Medveczky The use of drugs in mothers of offspring with neural-tube defects. Pharmacoepidemiol Drug Saf 2004; 13:443-55
|
|
Nakhai-Pour - Centrally acting, 2010
|
Nakhai-Pour Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol 2010; 89:147-54
|
|
Orbach - Methyldopa, 2013
|
Orbach Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol 2013; 208:301.e1-6
|
|
Redman - Methyldopa, 1976
|
Redman Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 1976; 2:753-6
|
|
Sibai - Methyldopa (Controls unexposed, sick), 1990
|
Sibai A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162:960-6; discussion 966-7
|
|
Su - Centrally acting (Controls unexposed, disease free), 2013
|
Su Pregnancy outcomes of anti-hypertensives for women with chronic hypertension: a population-based study. PLoS One 2013; 8:e53844
|
|
Su - Centrally acting (Controls unexposed, sick), 2013
|
Su Pregnancy outcomes of anti-hypertensives for women with chronic hypertension: a population-based study. PLoS One 2013; 8:e53844
|
|
Vaclavik - Methyldopa, 2024
|
Vaclavik, J. MATERNAL AND FETAL OUTCOMES OF VARIOUS ANTIHYPERTENSIVE TREATMENT REGIMENS DURING PREGNANCY: INSIGHTS FROM THE CZECH NATIONAL REGISTRY 2012-2022 Int. J. Hypertens. 2024; 42:e10-.
|
|
Van Zutphen - Centrally acting, 2014
|
Caton Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol Teratol 2008; 82:34-40 Van Zutphen AR Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. Obstet Gynecol 2014;123:309-17
|
|
Weitz - Methyldopa, 1987
|
Weitz Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet 1987; 25:35-40
|
|
Welt - Methyldopa, 1981
|
Welt The effects of prophylactic management and therapeutics on hypertensive disease in pregnancy: preliminary studies. Obstet Gynecol 1981; 57:557-65
|
